Our Pipeline
Apellis’ efforts are focused on developing complement immunotherapies. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad range of serious diseases.
The safety and efficacy of the agents for the indications under investigation have not been established. There is no guarantee that the outcome of these studies will result in approval by a Health Authority.
RARE DISEASE
Launch Marketed in the US
Phase II Initiate Ph 3 in 1H'22
Phase II Complete enrollment in 1H'22
Phase II Initiate Ph 3 in 1H'22
Phase II
Pre-clinical IND in 1H'23
Ophthalmology
Phase III Submit U.S. NDA in 2Q‘22
Pre-clinical IND in 1H’23
Pre-clinical
Neurology
Pre-clinical IND in 2H‘22
Pre-clinical
Pre-clinical
Multiple therapeutic areas
Pre-clinical Pre-clinical data in 1H’22
Pre-clinical
Pre-clinical
*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan **Initial IND for siRNA ***Pending regulattory feedback Potential to be registrational
To learn more about Apellis clinical trials go to clinicaltrials.gov